Helixgate

Helixgate

Uncategorized

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

Read More

Published

on

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial

Published

on

The advisory committee meeting—the FDA’s first drug-related adcomm in nine months—could have been a “more conceptual discussion” about the design of AstraZeneca’s Phase 3 trial of camizestrant in HER2-negative advanced breast cancer, former cancer regulator Harpreet Singh told BioSpace.

Continue Reading

Uncategorized

Summit shares descend as PD-1/VEGF asset misses early survival mark

Published

on

Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.

Continue Reading

Uncategorized

FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data

Published

on

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.

Continue Reading
Advertisement

Trending